Industry News
Avacta’s proprietary TMAC cancer therapy platform demonstrates successful proof-of-concept in pre-clinical study
Positive in vivo efficacy and pharmacokinetic data shows AVA04-VbP drug conjugate out-performed Bavencio immunotherapy
News & Articles
25
Selected Filters:
Industry News
Avacta and Daewoong Pharmaceutical form immunotherapy focused joint venture
Joint venture to develop next generation cell and gene therapies incorporating Affimer proteins
Industry News
LG Chem Life Sciences Expands Partnership with Avacta Group plc
LG Chem selects second and third drug targets following rapid progress in first program
Industry News
Avacta enters into collaboration and option agreement with ADC Therapeutics
New collaboration to focus on developing potent Affimer-drug conjugates
Product News
Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumor indications as the basis of bispecific and combination therapies
Industry News
Avacta Agrees Affimer Reagent Licensing Deal with New England Biolabs
Royalty-bearing license agreement to commercialize a product incorporating the Affimer technology
Product News
Avacta Group and Tufts University Collaborate to Develop Novel Drug Conjugate
Drug conjugate combines Avacta’s Affimer technology with conjugates developed at Tufts for precision delivery